



# PHARMANUTRA GROUP STAR CONFERENCE 2025

Milan, March 25-26th, 2025

# DISCLAIMER

This document has been prepared by Pharmanutra S.p.A. (the “Company”) for use during meetings with investors and financial analyst and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may not be reproduced or distributed, in whole or in part, by any person other than the Company.

This document may contain forward-looking statements about the Company based on current expectations and opinions developed by the Company, as well as based on current plans, estimates, projections and projects of the Company. These forward-looking statements are subject to significant risks and uncertainties (many of which are outside the control of Pharmanutra) which could cause a material difference between forward-looking information and actual future results. The Company does not make any guarantee that subsequent to the date of the document, there will not be any changes to the activities and/or earnings situation of the Company.

Any reference to past performance or trends or activities of the Company shall not be taken as a representation or indication that such performance, trends or activities will continue in the future.

This document does not constitute a proposal to execute a contract, an offer or invitation to purchase, subscribe or sell for any financial instrument and neither it or any part of it shall form the basis of or be relied upon in connection with any contract or commitment or investments decision whatsoever. Any decision to purchase, subscribe or sell for securities will have to be made independently of this presentation. Therefore, nothing in this presentation shall create any binding obligation or liability on the Company and its affiliates and any of their advisors or representatives.


Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any investor.

All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a comprehensive representation of the Company’s cash generation performance.

All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document and are expressly qualified in their entirety by the cautionary statements included elsewhere in this document. The financial projections are preliminary and subject to change; the Company undertakes no obligation to update or revise these forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. Inevitably, some assumptions will not materialize, and unanticipated events and circumstances may affect the ultimate financial results. Projections are inherently subject to substantial and numerous uncertainties and to a wide variety of significant business, economic and competitive risks, and the assumptions underlying the projections may be inaccurate in any material respect. Therefore, the actual results achieved may vary significantly from the forecasts, and the variations may be material.

By receiving this Presentation, you acknowledge and agree to be bound by the foregoing terms, conditions, limitations and restrictions.

# DPS VS STOCK PERFORMANCE




**2024 VS 2021**  
**+70% REVENUES**  
**+54% EBITDA**  
**+41% DPS**  
**-28% SHARE PRICE**

# PHARMANUTRA'S UNIQUENESS



# INTELLECTUAL PROPERTY PROTECTION

No player in the dietary supplements and medical devices industry has these **4 STRONG PILLARS IN ONE SINGLE COMPANY**



# SUCROSOMIAL® IRON MENTIONED IN THE GUIDELINE OF WHO

“

## **PharmaNutra S.p.A.: Sucrosomial Iron® mentioned in the guidelines of the World Health Organisation.**

The Group's patented and designed solution indicated as the only oral iron for anaemia in people with cardiovascular disease and diabetes.

 PHARMANUTRA

“The reference to Sucrosomial® Iron within the World Health Organisation Guidelines is an important recognition of the value of our patent, now of worldwide relevance, but also for the work carried out by our research and development department in recent years. This evidence gives us further impetus to continue to invest in research to further refine and improve Sucrosomial® Technology, and to ensure increasingly effective solutions both as a means of preventing and counteracting iron deficiency, and as supplementation in all areas where this condition is one of the most frequent complications”.

Germano Tarantino, Chief Scientific Officer  
of PharmaNutra S.p.A.

 PHARMANUTRA

[Read full press release](#)

# TWO PHARMANUTRA PRODUCTS IN THE TOP20 DIETARY SUPPLEMENTS SOLD IN ITALY


**SIDERAL FORTE**  
1°

**APPORTAL**  
13° 

|                               | MAT Valori (Mio€) | Trend MAT |
|-------------------------------|-------------------|-----------|
| <b>SIDERAL FORTE 20CPS</b>    | 36,4              | +8,8%     |
| ESOXX ONE 20BUST STICK 10ML   | 25,0              | +13,0%    |
| GRINTUSS ADULTI SCIR 180G     | 23,2              | +15,0%    |
| GRINTUSS PEDIATRIC SCIR 180G  | 22,9              | -6,0%     |
| MARIAL 20 ORAL STICK 15ML     | 19,5              | +12,2%    |
| CARNIDYN PLUS 20BUST          | 19,4              | +2,7%     |
| ENTEROLACTIS PLUS 30CPS       | 18,9              | +7,7%     |
| ARMOLIPID PLUS 60CPR          | 18,6              | -6,6%     |
| VSL3 10BUST                   | 17,3              | +6,5%     |
| YOVIS FLACONCINI 10FL OS      | 16,8              | +22,9%    |
| BETOTAL ADVANCE B12 30FL      | 13,8              | +11,2%    |
| ENTERELLE PLUS 24CPS          | 12,4              | +12,6%    |
| <b>APPORTAL 14BUST</b>        | 12,3              | +17,0%    |
| VICKS ZZZQUIL NATURA 60PAST   | 12,1              | +11,4%    |
| REUFLOR GOCCE 5ML             | 11,9              | -4,2%     |
| DICOFLOL GOCCE 5ML            | 11,8              | -2,5%     |
| NEOBIANACID 45CPR MASTICABILI | 11,2              | +10,1%    |
| BETOTAL 40CPR                 | 10,9              | -8,9%     |
| YOVIS STICK 10BUST            | 10,9              | +12,8%    |
| YOVIS CAPS 10CPS              | 10,8              | +13,0%    |

Since November 2019  
is N°1 Dietary  
Supplement sold in Italy

# WIDE INTERNATIONAL NETWORK



Our Partners are **exclusive distributors** in their territories.

Scientific knowledge and research activities are shared through **meetings** with the partner sales force and through an **e-learning portal**.

Partners are constantly supported from order to shipment by our **Operation Department**.

**Medical detailing and marketing experience** are shared with partners in order to support them to develop the **continuously growing business**.

PharmaNutra operates in **86 countries with 58 partners**, carefully selected among the best international pharmaceutical and nutraceutical companies.



# 2024 AND Q1 2025 RESULTS

# HIGHLIGHTS FY 2024

- **Solid and organic growth** in **revenue** and **EBITDA**, with increases of approximately **15%** and **17%**, respectively, compared to the previous year.
- **26,6% EBITDA margin** on net revenues. EBITDA margin on net revenues related to the **recurring business 31,4%** (30,4% in FY 2023).
- **Net Result € 16,6 M** (€ 12,8 M in FY 2023).
- Positive **Net Financial Position (Net cash)** of 5,6 million Euro (-2,6M at 31/12/23). Operating activities during the period generated **€ 20 million in cash**.
- Proposed Dividend Per Share of **€ 1,00**

+ 15%

**NET REVENUES € 115,5 M (€ 100,2 M IN 2023)**

+17%

**EBITDA € 31 M (€ 26,5 M IN 2023)**

+29%

**NET RESULT € 16,6 M (14,2% MARGIN ON REVENUES)**


5,6 Mio

**€ 20 M CASH FLOW FROM OPERATIONS**

+17,6%


**DPS OF 0,85 IN 2023**

# REVENUES EVOLUTION: SOLID ORGANIC GROWTH



# POSITIVE GROWTH TREND IN PROFITABILITY

**+18,4% CAGR 2017-2024 (+21,4% CAGR OF RECURRING BUSINESS)**






# NET FINANCIAL POSITION BACK TO POSITIVE

## NFP


The **significant** amount of cash generated by the operating activities (€ 20,5 M) allowed the Group to come back to a positive cash position net of outflows related to Capex (€ 3,6M), share buybacks (€ 551K) and dividend distribution (€ 8,2M).



# POSITIVE SALES TREND IN Q1 2025

The expected consolidated net revenues for the Q1 of 2025 **confirm the positive revenue growth trend.**


**We foresee double digit growth** driven by strong performance **in international markets.**



# OUTPERFORMING CONSENSUS OVER THE YEARS

# REVENUES EXPECTATIONS EXCEEDED THROUGH THE YEARS


**AVG. Growth rate vs CONSENSUS → +5,5%**  
**CAGR 2021-2024 REVENUES → +19,6%**





# EBITDA FOLLOWS THE TREND AND OVERCOME CONSENSUS

**AVG. Growth rate vs CONSENSUS → +16,5%**  
**CAGR 2021-2024 EBITDA → +18%**



**ESG**

 PHARMANUTRA

# ESG STATE OF THE ART

The Group obtained a score of 71/100 (**Silver Medal**) in the environmental impact assessment conducted by EcoVadis, ranking in the **Top 15% position**.


Additionally, in 2024, the CDP evaluation questionnaire was completed, resulting in a score of B.

The Group is also awaiting the finalization of the Omnibus decree on the modification of the CSRD. In the meantime, with the aim of integrating into the ESRS principles, the Gap Analysis between the current reporting with GRI and the ESRS one will be completed, and the Life Cycle Assessment is in the design phase.

We actively working in order to improve our ESG rating and we are confident that once the domotic system implemented at the end of 2024 is fully operational and data related to consumptions are available the rating will further improve.



71 /100  
92°  
percentile



# ESG ROADMAP



2023

2024

2025

2026

2027

Definition of ESG Strategy with targets and KPIs

Appointment of Sustainability Committee

New ESG compliant Headquarter

Creation of the ESG Operation Team

Training on ESG issues to all staff/functional managers (who are part of the ESG team)

Integration of a domotic systems for monitoring energy consumption

EcoVadis certification with a score of 71/100 (Silver Medal)  
CDP certification with a score of B for climate

Life Cycle Assessment project

GAP Analysis between GRI and ESRS reporting

Improve the environmental reporting and the setting of environmental goals to be achieved

Implementation of a personalized incentive and growth program for each employee

Agreement reached at the beginning of the year for the donation of expiring products through the Regusto platform

Definition of ESG KPIs

Value chain engagement

Assessment of the adoption of an ISO 14001 - compliant environmental management system

Assessment of the adoption of an ISO 45001

Development of software and information system compliant with the CSRD (awaiting the finalization of Omnibus decree)



# BUSINESS GROWTH DRIVERS

# PHARMANUTRA USA STRATEGIC PLAN 2025-2027

In **2023 and 2024** set up of our **HQ in Miami**, creating the basis for **digital marketing and e-commerce initiatives** and opening contacts with **hospital groups and doctors**

From January **2025 new strategic plan** implanted starting together with a **primary international consulting firm**

Focus on **three different distribution channels** aiming at exploiting full potential of US market

**E-commerce  
DTC**



**Retail Chains**  
Drugstore  
Mass Retail  
Club stores




**Hospital  
networks**



First results are expected in 2H and **are planned to be progressively and significantly consolidated over the next 2 years.**

# EXPECTED US REVENUES 2025-2027



|                             |       |      |      |      |      |
|-----------------------------|-------|------|------|------|------|
| Units (K)                   | 0,8   | 3    | 29   | 118  | 353  |
| Ratio vs Italy sales volume | 0,02% | 0,1% | 0,6% | 2,1% | 5,9% |

# CHINA: FULL DIGITAL DISTRIBUTION APPROACH

Since 2022 built a **strong presence in China** through **4 online platforms**

TMALL GLOBAL  
天猫国际  
TMALL



DOUYIN (TikTok)



小红书RED  
RED SHOP  
(Instagram)



WECHAT  
WEIBO (chinese Twitter)



The online supplement Chinese market size is around **13,5 billion €**.  
So far in China Pharmedutra has a **client basis** of almost **60.000**  
**unique buyer** with **30% of repeat customers**

PHARMANUTRA

Collaboration with **influencers** by **posting stories, reels** and  
conducting **live streaming event**




In 2024 started **developing digital visibility of scientific assets**  
through publications on Nature China and meetings with HCPs





# EXPECTED CHINA REVENUES 2025-2027



|                             |      |      |      |      |      |
|-----------------------------|------|------|------|------|------|
| Units (K)                   | 22   | 86   | 300  | 368  | 552  |
| Ratio vs Italy sales volume | 0,5% | 1,8% | 5,9% | 6,7% | 9,3% |

# R&D PIPELINE: 162 PROTOTYPES IN DEVELOPMENT FOR 15 INNOVATIVE PRODUCTS



## 5 PRODUCTS

→ Intended for children with macro/micro nutrients deficiencies  
→ Pediatric field



## 4 PRODUCTS

→ Intended for adults with macro/micro nutrients deficiencies  
→ orthopedic, rheumatology and geriatric field



## 4 PRODUCTS

→ Designed for athletes to enhance their performance  
→ Sport nutrition field




## 2 PRODUCTS

→ Intended for physical and mental fatigue recovery  
→ Designed for adults




# PHARMANUTRA 2030

## SALES DEVELOPMENT



## PROFITABILITY DEVELOPMENT





 PHARMANUTRA